Advanced SearchNewsfeedFollowed Companies

Akcea Therapeutics's Competitors, Revenue, Number of Employees, Funding and Acquisitions

Akcea Therapeutics develops and commercializes RNA-targeted antisense therapeutics for the treatment of cardiometabolic ... Read more

Based on data from Akcea Therapeutics's latest SEC filings

Annual Revenue

Based on data from Akcea Therapeutics's latest SEC filings

Employees

Damien McDevitt's photo - CEO of Akcea Therapeutics

CEO

Damien McDevitt

CEO Approval Rating

90/100

OVERVIEW

Founded:

2015

Headquarters:

Boston, Massachusetts
Greater Boston

Status:

PublicNASDAQAKCA

Industry Sector:

Biotechnology,
Pharmaceuticals

SIC Code:

2836NAICS listing »

2834NAICS listing »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is CymaBay a competitor of Akcea Therapeutics?

I don't know

Trending News for Akcea Therapeutics and Akcea Therapeutics's Competitors

May 28, 2020

The Pharma Letter

Akcea and Ionis report positive results for Tegsedi in hATTR

Akcea Therapeutics today announced publication of long-term data from the open-label extension (OLE).... See more »

May 27, 2020

MarketScreener

GENFIT: Publication of the 2019 Universal Registration Document and the 2019 Annual Report on Form 20-F

(marketscreener.com) Lille , Cambridge , May 27, 2020 - GENFIT , a late-stage biopharmaceutical compa... See more »

May 26, 2020

Seeking Alpha

FDA accepts Alnylam application for lumasiran for rare kidney stone disorder

See more »

Competitive Analysis

TOP COMPETITORS OR ALTERNATIVES

Alnylam is Akcea Therapeutics's #1 rival. Alnylam was founded in 2002 in Cambridge, Massachusetts. Like Akcea Therapeutics, Alnylam also operates in the Pharmaceuticals space. Alnylam generates $271.1M less revenue than Akcea Therapeutics.

Eidos Therapeutics is one of Akcea Therapeutics's top competitors. Eidos Therapeutics is headquartered in San Francisco, California, and was founded in 2013. Like Akcea Therapeutics, Eidos Therapeutics also works within the Biotechnology sector. Eidos Therapeutics generates 5.44% the revenue of Akcea Therapeutics.

NGM Bio is seen as one of Akcea Therapeutics's top competitors. NGM Bio was founded in 2008, and its headquarters is in South San Francisco, California. Like Akcea Therapeutics, NGM Bio also works within the Biotechnology sector. NGM Bio has 62 fewer employees than Akcea Therapeutics.

RANK

COMPANY

LEADERSHIP

CEO SCORE

EMPLOYEES

TOTAL FUNDING

REVENUE

Damien McDevitt

CEO

- -
248
$668.2M
$490.8M
1

John Maraganore

CEO

100/100
1,065
$417.5M
$285.9M
2

Neil Kumar

CEO

86/100
24
$170.3M
$26.7M
3

David J. Woodhouse

CEO

92/100
186
$344.8M
$102.4M
4

Sujal Shah

President & CEO

89/100
43
$86.6M
$5.2M
5

Pascal Prigent

CEO

82/100
200
$521.9M
$8.5M
6

Dennis Smith

CEO

70/100
72
- -
$28M
7

Wendy Shusko

President & CEO

67/100
84
- -
$5M
8

Robert Irene

President

70/100
10
- -
$10M
9

Frederick D. Sancilio

Chairman & CEO

78/100
278
$20M
$7.8M
10

CEO

- -
450
$344.1M
$66.6M
The top 10 competitors in Akcea Therapeutics' competitive set are Alnylam, Eidos Therapeutics, NGM Bio, CymaBay, Genfit, Masters, WellSpring, Armada Health Care, Sancilio and Company and Ablynx. Together they have raised over 1.9B between their estimated 2.7K employees. Akcea Therapeutics has 248 employees and is ranked 4th among it's top 10 competitors. The top 10 competitors average 241.

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$490.8M

Akcea Therapeutics's revenue is the ranked 1st among it's top 10 competitors. The top 10 competitors average 94.3M. Over the last three quarters, Akcea Therapeutics's revenue has grown by 942.3%. Specifically, in Q4 2019's revenue was $277.5M; in Q3 2019, it was $20.6M; in Q2 2019, it was $26.6M.

Acquisitions

No recent acquisitions found related to Akcea Therapeutics

Akcea Therapeutics Funding History

Since Akcea Therapeutics was founded in 2015, it has participated in 2 rounds of funding. In total Akcea Therapeutics has raised $668.2M. Akcea Therapeutics' last funding round was on Dec 2015 for a total of $543.2M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Equity
Dec 2015
$543.2M
-
IPO
Jul 2017
$125M
-

Total Funding: $668.2M

Since Akcea Therapeutics was founded in 2015, it has participated in 2 rounds of funding. In total Akcea Therapeutics has raised $668.2M. Akcea Therapeutics' last funding round was on Dec 2015 for a total of $543.2M

Investments

No recent investments found related to Akcea Therapeutics

Akcea Therapeutics News

May 11, 2020Zacks

Why Akcea (AKCA) Stock Might be a Great Pick

Akcea (AKCA) has seen solid earnings estimate revision activity over the past month, and belongs to a... See more »
May 6, 2020Seeking Alpha

Akcea Therapeutics, Inc. (AKCA) CEO Damien McDevitt on Q1 2020 Results - Earnings Call Transcript

See more »
May 5, 2020Zacks

Akcea Therapeutics (AKCA) Reports Q1 Loss, Misses Revenue Estimates

Akcea Therapeutics (AKCA) delivered earnings and revenue surprises of 6.67% and -70.23%, respectively... See more »
April 28, 2020Zacks

Akcea Therapeutics (AKCA) Q1 Earnings Expected to Decline

Akcea Therapeutics (AKCA) doesn't possess the right combination of the two key ingredients for a like... See more »
April 21, 2020Benzinga

Akcea Therapeutics to Hold First Quarter 2020 Financial Results Webcast

BOSTON, April 21, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned a... See more »
April 10, 2020MarketScreener

Investigation on Behalf of Akca Shareholders

(marketscreener.com) Thornton Law Firm LLP, a law firm that represents shareholders in recovery actio... See more »
March 24, 2020MarketScreener

Akcea Therapeutics Announces Appointment of Dr. Damien McDevitt as CEO

(marketscreener.com) BOSTON, March 24, 2020 -- Akcea Therapeutics, Inc. , a majority-owned affiliate ... See more »

Akcea Therapeutics Press Releases

April 29, 2020NewsFile

Nationally Ranked Shareholder Rights Firm Labaton Sucharow Announces Proprietary Investigation of Akcea Therapeutics, Inc. (AKCA)

New York, New York--(Newsfile Corp. - April 29, 2020) - Labaton Sucharow LLP, a leading and award win... See more »
April 10, 2020centralcharts

Investigation on Behalf of Akca Shareholders

Boston, Massachusetts--(Newsfile Corp. - April 10, 2020) - Thornton Law Firm LLP, a law firm that rep... See more »
November 13, 2019centralcharts

Akcea Therapeutics to Present at Upcoming Investor Conferences

BOSTON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned af... See more »
September 16, 2019centralcharts

Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual Meeting

Data show >90% knockdown of TTR following administration in healthy volunteers Positive safety and to... See more »
August 8, 2019CentralCharts

New England Journal of Medicine Publishes Results from Pivotal Study of WAYLIVRA® (volanesorsen) in Patients with Familial Chylomicronemia Syndrome

Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharm... See more »
July 16, 2019GlobeNewswire

hATTR Compass Genetic Testing Program Continues to Expand and Enable Diagnosis and Treatment of Hereditary ATTR Amyloidosis One Year Following Launch

Akcea and Ambry Genetics grow partnership, providing easily accessible, no-cost, confidential genetic... See more »
May 8, 2019GlobeNewswire

Akcea Reports Financial Results and Highlights for First Quarter 2019

Achieved First Quarter 2019 TEGSEDI® (inotersen) Global Net Product Revenues of $7 Million... See more »

Akcea Therapeutics Videos

Headquarters

22 Boston Wharf Road 9th Floor

Boston, Massachusetts02210

617-207-0202

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Akcea Therapeutics develops and commercializes RNA-targeted antisense therapeutics for the treatment of cardiometabolic lipid disorders. Akcea Therapeutics was founded in 2015. Akcea Therapeutics' headquarters is located in Boston, Massachusetts, USA ...

CEO

Akcea Therapeutics's CEO, Damien McDevitt, currently has an approval rating of 90%. Akcea Therapeutics's primary competitors are Alnylam, Eidos Therapeutics & NGM Bio.

Website

akceatx.com

Frequently Asked Questions about Akcea Therapeutics

  1. When was Akcea Therapeutics founded?

    Akcea Therapeutics was founded in 2015

  2. Who is Akcea Therapeutics's CEO?

    Akcea Therapeutics's CEO is Damien McDevitt

  3. How much revenue does Akcea Therapeutics generate?

    Akcea Therapeutics generates $490.8M in revenue

  4. How much funding does Akcea Therapeutics have?

    Akcea Therapeutics has historically raised $668.2M in funding

  1. Where is Akcea Therapeutics's headquarters?

    Akcea Therapeutics's headquarters is in Boston Massachusetts, USA

  2. How many employees does Akcea Therapeutics have?

    Akcea Therapeutics has 248 employees

  3. What sector does Akcea Therapeutics operate in?

    Akcea Therapeutics is in Biotechnology, Pharmaceuticals

  4. Who are Akcea Therapeutics's competitors?

    Akcea Therapeutics's top competitors are Alnylam, Eidos Therapeutics, NGM Bio
Stay up-to-date with the latest news on Akcea Therapeutics